374 related articles for article (PubMed ID: 22696212)
1. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
8. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
10. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
12. [Myelodysplastic syndromes].
Thol F; Heuser M; Ganser A
Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
14. Laboratory and clinical risk assessment to treat myelodysplatic syndromes.
Gidaro A; Deliliers GL; Gallipoli P; Arquati M; Wu MA; Castelli R
Clin Chem Lab Med; 2016 Sep; 54(9):1411-26. PubMed ID: 26812791
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes current treatment algorithm 2018.
Steensma DP
Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
[TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Wang C; Sallman DA
Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
[TBL] [Abstract][Full Text] [Related]
18. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Feld J; Belasen A; Navada SC
Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
[TBL] [Abstract][Full Text] [Related]
20. The lower risk MDS patient at risk of rapid progression.
Mittelman M; Oster HS; Hoffman M; Neumann D
Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]